Magle Chemoswed Holding Reports Financial Results For First Quarter 2023

MFN Publicerad: 19 Apr 2023 08:30

Today, on 19 April 2023, Magle Chemoswed Holding AB (publ) has published its interim report for Q1 2023.

JAN-MAR 2023 KEY INDICATORS

Net sales amounted to 38.7 MSEK (30.2)
EBITDA equalled 7.5 MSEK (7.7)
Operating profit (EBIT) is 4.3 MSEK (4.6)
Profit after tax amounted to 2.9 MSEK (4.1)
Earnings per share SEK 0,3 (0,4) per share

“During the first quarter of 2023, we expanded our production capacity, completed the study on SmartPAN®, stepped up the program for international registrations of our degradable starch microsphere products and delivered increased revenues and profit.” says Justin Pierce, CEO of Magle Group.

The full report is available at https://maglegroup.com/financial-reports/

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and https://maglegroup.com/ and www.maglepharmacept.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at [email protected] or +46 (0)8-580 065 99.

Börskollen

För dig med koll på börsen

Pressmeddelande

Magle Chemoswed Holding Reports Financial Results For First Quarter 2023

Bifogade filer

Nyheter om Magle Chemoswed

Läses av andra just nu

Om aktien Magle Chemoswed

Senaste nytt